Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes

Journal of Clinical Investigation

Volumn 111, Issue 10, 2003, Pages 1487-1496

  Bai, Xue Feng ^a   Liu, Jinqing ^a   Li, Ou ^a   Zheng, Pan ^a   Liu, Yang ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS ANTIGEN; DNA BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; RAG2 PROTEIN, MOUSE; TUMOR REJECTION ANTIGEN P815A, MOUSE; V(D)J RECOMBINATION ACTIVATING PROTEIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CLONE; DISEASE MODEL; GENETIC DRIFT; GENETICS; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLASMACYTOMA; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; CLONE CELLS; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EPITOPES; GENETIC DRIFT; IMMUNOTHERAPY, ADOPTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PLASMACYTOMA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 85047690959     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI17656     Document Type: Article

References (41)

1. Ciurea, A., et al. 2000. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc. Natl. Acad. Sci. U. S. A. 97:2749-2754.
2. Parren, P.W., Moore, J.P., Burton, D.R., and Sattenrau, Q.J. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity, AIDS. 13(Suppl. A):S137-S162.
3. Pircher, H., et al. 1990. Viral escape by selection to cytotoxic T cell-resistant virus variants in vivo. Nature. 34:629-633.
4. Goulder, P.J., et al. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 412:334-338.
5. Ciurea, A., et al. 2001 CD4 T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 7:795-800.
6. Khong, H.T., and Restifo, N.P. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999-1005.
7. Wick, M., et al. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-238.
8. Ochsenbein, A.F., et al. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 96:2233-2238.
9. Shrikant, P., Khoruts, A., and Mescher, M. F. 1999. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11:483-493.
10. Zheng, P., et al. 1998. Proto-oncogene PML controls genes devoted to MHC class 1 antigen presentation. Nature. 396:373-376.
11. Seliger, B., Maeuret, M.J., and Ferrone, S. 1997. TAP off-tumors on. Immunol. Today. 18:292-299.
12. Uyttenhove, C., Maryanski, J., and Boon, T. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040-1052.
13. Sarma, S., et al. 1999. Cytotoxic T lymphocytes to an unmutated tumor antigen P1A: normal development but restrained effector function. J. Exp. Med. 189:811-820.
14. Bai, X.F., et al. 2001. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J. Immunol. 167:3936-3943.
15. + T lymphocytes in vivo. J. Exp. Med. 194:1339-1348.
16. Smith, J.D., Myers, N.B., Gorka, J., and Hansen, T.H. 1993. Model for the in vivo assembly of nascent Ld class I molecules and for the expression of unfolded Ld molecules at the cell surface. J. Exp. Med. 178:2035-2046.
17. Lethe, B., van den Eynde, B., van Pel, A., Corradin, G., and Boon, T. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:2283-2288.
18. Evavold, B.D., Sloan-Lancaster, J., and Allen, P.M. 1993. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol. Today. 14:602-609.
19. Hogquist, K.A., et al. 1994. T cell receptor antagonist peptides induce positive selection. Cell. 76:17-27.
20. Butz, E.A., and Bevan, M.J. 1998. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity. 8:167-175.
21. Lee, P.P., et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
22. Romero, P., et al. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641-1650.
23. Ramarathinam, L., Castle, M., Wu, Y., and Liu, Y. 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in che induction, recruitment, and effector function of antitumor T cells J. Exp. Med. 179:1205-1214.
24. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
25. Gregory, S.G., et al. 2002. A physical map of the mouse genome. Nature. 418:743-750.
26. Dudley, M.E., and Roopenian, D.C. 1996. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methyl-cholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184:441-447.
27. Tanaka, Y., and Tevethia, S.S. 1988. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J. Immunol. 140:4348-4354.
28. Lill, N.L., Tevechia, M.J., Hendrickson, W.G., and Tevethia, S.S. 1992. Cytotoxic T lymphocytes (CTL) against a transforming gene product select £or transformed cells with point mutations within sequences encoding CTL recognition epitopes. J. Exp. Med. 176:449-457.
29. Dummer, W., et al. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110:185-192. doi:10.1172/JCI200215175.
30. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 295:850-854.
31. Jameson, S.C., Hogquist, K.A., and Bevan, M.J. 1995. Positive selection of thymocytes. Annu. Rev. Immunol. 13:93-126.
32. Reich, Z., et al. 1997. Ligand-specific oligomerization of T-cell receptor molecules. Nature. 387:617-620.
33. McMichael, A. 1998. T cell responses and viral escape. Cell. 93:673-676.
34. Borrow, P., and Shaw, G.M. 1998. Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo? Immunol. Rev. 164:37-51.
35. Romero, P., et al. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med 188:1641-1650.
36. Coulie, P.G., et al. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. U. S. A. 98:10290-10295.
37. Stanislawski, T., et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:962-970.
38. Boczkowski, D., Nair, S.K., Nam, J.H., Lyerly, H.K., and Gilboa, E. 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60:1028-1034.
39. Banchereau, J., et al. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(-) progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451-6458.
40. Srivastava, P.K., and Udono, H. 1994. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6:728-732.
41. Beck-Engeser, G.B., et al. 2001. Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. J. Exp. Med. 194:285-300.